|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Risk MC, Knudsen BS, Coleman I, Dumpit RF,
Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS and Lin DW:
Differential gene expression in benign prostate epithelium of men
with and without prostate cancer: Evidence for a prostate cancer
field effect. Clin Cancer Res. 16:5414–5423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang W and Mo ZN: Advances in
prostate-specific membrane antigen targeted therapies for prostate
cancer. Zhonghua Nan Ke Xue. 16:547–551. 2010.(In Chinese).
PubMed/NCBI
|
|
4
|
Cheng L, Song SY, Pretlow TG, Abdul-Karim
FW, Kung HJ, Dawson DV, Park WS, Moon YW, Tsai ML, Linehan WM, et
al: Evidence of independent origin of multiple tumors from patients
with prostate cancer. J Natl Cancer Inst. 90:233–237. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Zhao X, Chen L, Guo H, Lv F, Jia K,
Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of
novel selective vascular endothelial growth factor receptor-2
inhibitor YN968D1 in patients with advanced malignancies. BMC
Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heston WD: Significance of
prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase
and membrane folate hydrolase. Urologe A. 35:400–407. 1996.(In
German). View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bander NH, Nanus DM, Milowsky MI,
Kostakoglu L, Vallabahajosula S and Goldsmith SJ: Targeted systemic
therapy of prostate cancer with a monoclonal antibody to
prostate-specific membrane antigen. Semin Oncol. 30:667–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bander NH, Trabulsi EJ, Kostakoglu L, Yao
D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM
and Goldsmith SJ: Targeting metastatic prostate cancer with
radiolabeled monoclonal antibody J591 to the extracellular domain
of prostate specific membrane antigen. J Urol. 170:1717–1721. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elsässer-Beile U, Reischl G, Wiehr S,
Bühler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla HJ and
Pichler BJ: PET imaging of prostate cancer xenografts with a highly
specific antibody against the prostate-specific membrane antigen. J
Nucl Med. 50:606–611. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang AX, Murelli RP, Barinka C, Michel J,
Cocleaza A, Jorgensen WL, Lubkowski J and Spiegel DA: A remote
arene-binding site on prostate specific membrane antigen revealed
by antibody-recruiting small molecules. J Am Chem Soc.
132:12711–12716. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kularatne SA, Wang K, Santhapuram HK and
Low PS: Prostate-specific membrane antigen targeted imaging and
therapy of prostate cancer using a PSMA inhibitor as a homing
ligand. Mol Pharm. 6:780–789. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maresca KP, Hillier SM, Femia FJ, Keith D,
Barone C, Joyal JL, Zimmerman CN, Kozikowski AP, Barrett JA,
Eckelman WC and Babich JW: A series of halogenated heterodimeric
inhibitors of prostate specific membrane antigen (Psma) as
radiolabeled probes for targeting prostate cancer. J Med Chem.
52:347–357. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bartsch G, Horninger W, Klocker H,
Reissigl A, Oberaigner W, Schönitzer D, Severi G, Robertson C and
Boyle P: Tyrol Prostate Cancer Screening Group: Prostate cancer
mortality after introduction of prostate-specific antigen mass
screening in the federal state of tyrol, Austria. Urology.
58:417–424. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Labrie F, Candas B, Dupont A, Cusan L,
Gomez JL, Suburu RE, Diamond P, Lévesque J and Belanger A:
Screening decreases prostate cancer death: First analysis of the
1988 Quebec prospective randomized controlled trial. Prostate.
38:83–91. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schroder FH, Hugosson J, Roobol MJ,
Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,
Zappa M, et al: Screening and prostate-cancer mortality in a
randomized European study. N Engl J Med. 360:1320–1328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rajasekaran AK, Anilkumar G and
Christiansen JJ: Is prostate-specific membrane antigen a
multifunctional protein? Am J Physiol Cell Physiol. 288:C975–C981.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghosh A and Heston WD: Tumor target
prostate specific membrane antigen (PSMA) and its regulation in
prostate cancer. J Cell Biochem. 91:528–539. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mohler JL, Kantoff PW, Armstrong AJ,
Bahnson RR, Cohen M, D’Amico AV, Eastham JA, Enke CA, Farrington
TA, Higano CS, et al: National comprehensive cancer network:
Prostate cancer, version 1.2014. J Natl Compr Canc Netw.
11:1471–1479. 2013.PubMed/NCBI
|
|
19
|
Auprich M, Bjartell A, Chun FK, de la
Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B and
van der Poel H: Contemporary role of prostate cancer antigen 3 in
the management of prostate cancer. Eur Urol. 60:1045–1054. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng SL, Sun J, Wiklund F, Smith S,
Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Bälter K, et al:
Cumulative association of five genetic variants with prostate
cancer. N Engl J Med. 358:910–919. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
De Wever W, Coolen J and Verschakelen JA:
Integrated PET/CT and cancer imaging. JBR-BTR. 92:13–19.
2009.PubMed/NCBI
|
|
22
|
Del Vecchio S, Zannetti A, Fonti R,
Iommelli F, Pizzuti LM, Lettieri A and Salvatore M: PET/CT in
cancer research: From preclinical to clinical applications.
Contrast Media Mol Imaging. 5:190–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patel CN, Goldstone AR, Chowdhury FU and
Scarsbrook AF: FDG PET/CT in oncology: ‘Raising the bar’. Clin
Radio. 165:522–535. 2010. View Article : Google Scholar
|
|
24
|
Picchio M, Briganti A, Fanti S,
Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN and
Thalmann GN: The role of choline positron emission
tomography/computed tomography in the management of patients with
prostate-specific antigen progression after radical treatment of
prostate cancer. Eur Urol. 59:51–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
